Drug Profile
Mesalazine controlled-release - AbbVie
Alternative Names: Asacol HD; Delzicol; Mesalazine controlled-release capsules - AbbVie; Mesalazine controlled-release tablets - AbbVie; Mesalazine delayed-release capsules - AbbVie; Mesalazine delayed-release tablets - AbbVieLatest Information Update: 11 Apr 2022
Price :
$50
*
At a glance
- Originator Procter & Gamble
- Developer AbbVie; Warner Chilcott
- Class Aminosalicylic acids; Anti-inflammatories; Antineoplastics; Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ulcerative colitis
Most Recent Events
- 07 Apr 2022 AbbVie plans a phase III trial for Ulcerative Colitis (In Children, In adolescents) in USA and Puerto Rico (PO, Capsule) in May 2022(NCT05316220)
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc